Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

NCT00130000 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

87

Enrollment

NIH

Sponsor class

Conditions

Paroxysmal Hemoglobinuria, Nocturnal

Interventions

DRUG: Eculizumab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)